NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Lakefront Biotherapeutics NV LKFT
11 fiscal years on record · EUR · FY2025 reported · SEC filings only
Growth
EUR 1.1B
Revenue, FY2025 · full 11-year series below
Revenue €B
Net income €B
FY2025 · Revenue 1.1 · Net income 0.3
Compound annual growth
Revenue compounded at +18.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
29 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 26.5% · Net 28.9%
ROE
Not available in our data for this period.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · EUR
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 1.1 | 0.3 | 0.2 | 0.2 | 0.2 | 0.5 | 0.8 | 0.3 | 0.1 | 0.1 | 0.0 |
| Operating income €B | 0.3 | −0.2 | −0.1 | −0.1 | −0.2 | −0.2 | 0.4 | −0.0 | −0.1 | −0.0 | −0.1 |
| EBITDA €B | · | · | · | · | · | · | · | · | · | · | · |
| Income tax €B | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income €B | 0.3 | 0.1 | 0.2 | −0.2 | −0.1 | −0.3 | 0.1 | −0.0 | −0.1 | 0.1 | −0.1 |
| Free cash flow €B | −0.3 | −0.3 | −0.4 | −0.5 | −0.6 | −0.5 | 3.2 | −0.2 | −0.2 | 0.2 | −0.1 |
| EPS, diluted € | 4.87 | 1.12 | 3.21 | −3.32 | −1.58 | −4.69 | 2.49 | −0.56 | −2.34 | 1.14 | −3.32 |
| Dividend / sh € | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Lakefront Biotherapeutics NVvsSanofiSame industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsGrifols SASame industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsEvotec SESame industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsAscendis Pharma A/SSame industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsNanobiotix S.a.Same industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsProQR Therapeutics N.v.Same industry: Pharmaceutical PreparationsLakefront Biotherapeutics NVvsInventiva S.a.Same industry: Pharmaceutical Preparations
Provenance
Company facts, as filed
How we verify · 0 failures in 44 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 47 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C9
Fiscal year endsnot stated in the filings
Data on record since2015